PADNI: Parkinson's and Alzheimer's disease Dimensional Neuroimaging Initiative
- Conditions
- Alzheimer's disease (AD), Parkinson's disease (PD) and AD/PD related disorders
- Registration Number
- JPRN-UMIN000036297
- Lead Sponsor
- atinal Center of Neurology and Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 615
Not provided
1) Existence of significant diseases that may affect the central nervous system other than the target disease of this research, such as neurodegenerative diseases (other than AD/PD related diseases), severe cerebrovascular diseases, neuroimmune diseases, and head injuries. 2) Existence of significant MRI abnormalities, which may affect cognitive function. 3) Drug-induced parkinsonism is likely. 4) SWEDD (Scans Without Evidence of Dopaminergic Deficit). 5) Contraindications to MRI. 6) Hypersensitivity to tracers such as 18F-GE067 and 123I-FP-CIT. 7) Medical history of schizophrenia; major depressive disorder or bipolar disorder defined by DSM-IV within a year. 8) A history of alcoholism and drug dependence defined by DSM-IV within the past two years. 9) Severe mental symptoms that make it difficult to comply with the protocol within the past three months 10) Serious systemic disease or an unstable disease. 11) Systemic disease affecting cognitive function such as infectious disease and metabolic disease. 12)Participant admitted to a nursing home or another hospital. 13) If a participant is planning to participate in a clinical intervention trial at the time of enrollment. 14) Any case in which a researcher or consulting doctor judges that the study is not appropriate for a particular participant.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of neural network functions and brain structures by means of MRI analysis, especially from the viewpoints of the PADNI concept, putting emphasis on chronological changes of the measures and their differences across groups.
- Secondary Outcome Measures
Name Time Method 1. Transition rate from preclinical AD to MCI or AD 2. Transition rate from prodromal PD/DLB to PD or DLB 3. Changes of biomarkers including blood and cerebrospinal fluid 4. Changes of amyloid accumulation in amyloid PET 5. SBR of DAT-SPECT and statistical index of image analysis 6. Clinical index: Correlation between each group or correlation between MRI evaluation index and clinical indicators in each group 7. If a participant dies during the study, we will consider an autopsy.